NASDAQ : PRQR
ProQR Therapeutics N.V. — Key statistics
Healthcare · Biotechnology · Netherlands
Last price 1.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 203.21M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 196.16M |
| Enterprise Value | 79.84M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 141.12M |
| Shares Outstanding | 141.12M |
| Shares Change (YoY) | +8.75% |
| Shares Change (QoQ) | +4.36% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | 37.27% |
| Float | 91.44M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.32 |
| Forward PS | 11.10 |
| PB Ratio | 2.16 |
| P/TBV Ratio | 2.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.49 |
| Quick Ratio | 3.41 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -46.13 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -57.40% |
| Return on Assets (ROA) | -19.76% |
| Return on Invested Capital (ROIC) | -29.99% |
| Return on Capital Employed (ROCE) | -43.43% |
| Weighted Average Cost of Capital (WACC) | 5.31% |
| Revenue Per Employee | $112,796 |
| Profits Per Employee | -$257,373 |
| Employee Count | 187 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 29,704 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -47.55% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 1.69 |
| Relative Strength Index (RSI) | 40.78 |
| Average Volume (20 Days) | 958,936 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.91M |
| Short Previous Month | 2.87M |
| Short % of Shares Out | 2.71% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.74 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 21.05M |
| Gross Profit | 21.05M |
| Operating Income | -48.96M |
| Pretax Income | -48.00M |
| Net Income | -48.03M |
| EBITDA | -47.87M |
| EBIT | -48.96M |
| Loss Per Share | -$0.46 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 133.81M |
| Total Debt | 17.49M |
| Net Cash | 116.32M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 90.80M |
| Book Value Per Share | 0.64 |
| Working Capital | 99.12M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -54.80M |
| Capital Expenditures | -1.29M |
| Depreciation & Amortization | 1.06M |
| Net Borrowing | -2.20M |
| Free Cash Flow | -56.09M |
| FCF Per Share | -$0.40 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -232.60% |
| Pretax Margin | -228.04% |
| Profit Margin | -228.18% |
| EBITDA Margin | -227.44% |
| EBIT Margin | -232.60% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.75% |
| Shareholder Yield | -8.75% |
| Earnings Yield | -32.93% |
| FCF Yield | -28.59% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.78 |
| Price Target Difference | 459.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 13.61% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.28 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |